Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
AbbVie Declares Quarterly Dividend PR Newswire - Thu Jun 18, 3:05PM CDT

NORTH CHICAGO, Ill. , June 18, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. 

ABBV : 216.49 (-2.14%)
Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance PR Newswire - Tue Jun 16, 7:00AM CDT

IRVINE, Calif. , June 16, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM...

ABBV : 216.49 (-2.14%)
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results PR Newswire - Fri Jun 12, 2:00AM CDT

NORTH CHICAGO, Ill. , June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA)...

ABBV : 216.49 (-2.14%)
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics PR Newswire - Wed Jun 10, 7:00AM CDT

IRVINE, Calif. , June 10, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced the release of What Consumers Really Want , the latest installment in The Aesthetics Evolution...

ABBV : 216.49 (-2.14%)
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 PR Newswire - Mon Jun 8, 7:00AM CDT

NORTH CHICAGO, Ill. , June 8, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical...

ABBV : 216.49 (-2.14%)
AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire - Tue Jun 2, 7:00AM CDT

NORTH CHICAGO, Ill. , June 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. Management will participate...

ABBV : 216.49 (-2.14%)
Abbvie Inc logo and meds- by Ascannio via Shutterstock
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector? Barchart - Fri May 29, 8:33AM CDT

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

XLV : 149.40 (-0.87%)
JNJ : 228.39 (-2.48%)
ABBV : 216.49 (-2.14%)
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia PR Newswire - Fri May 29, 7:00AM CDT

NORTH CHICAGO, Ill. , May 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has authorized an expanded label for VENCLYXTO ® (venetoclax) to include...

ABBV : 216.49 (-2.14%)
MarketBeat.com
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? MarketBeat - Thu May 28, 8:15AM CDT

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

HIMS : 35.47 (+11.23%)
NVO : 43.19 (-0.76%)
LLY : 1,098.57 (-1.21%)
ABBV : 216.49 (-2.14%)
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options PR Newswire - Wed May 27, 5:18PM CDT

- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting - DECNUPAZ...

ABBV : 216.49 (-2.14%)

Barchart Exclusives

From ‘Hold’ to ‘Buy’: Here Is Why Truist Just Changed Its Mind on DDOG Stock Barchart - 16 minutes ago
Datadog stock has been upgraded to a "Buy" by Truist with a price target of $300. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.